Business Wire

BULK-DATA-CENTERS

30.11.2021 08:07:05 CET | Business Wire | Press release

Share
DE-CIX Expands to the Nordics in Cooperation With Bulk Data Centers

DE-CIX , the world’s leading Internet Exchange (IX) operator and home to the largest carrier and data center neutral interconnection ecosystem globally, today announces its expansion to the Nordic region. DE-CIX has partnered with Bulk Data Centers , which will house DE-CIX IX platforms in Oslo, Norway (OS-IX), Kristiansand, Norway (Campus N01), as well as in Esbjerg, Denmark (Campus DK01). DE-CIX will also be opening IX platforms in Finland.

DE-CIX’s expansion into the Nordic region will open the Nordics to international customers, providing 100 percent green-powered Internet Exchanges through Bulk’s data centers. In addition, local Nordic customers will now get faster and more efficient access to global internet exchange services.

“The Nordic region comprises some of the world’s most highly developed digital markets,” says Ivo Ivanov, CEO of DE-CIX International, on the company’s expansion to Northern Europe. “However, the interconnection infrastructure available in the region does not match the digital maturity of the economy in the Nordics. DE-CIX has seen strong support from the Nordic data center community for our plans to expand to the region, in which we will localize our interconnection capabilities for these markets, at the same time as integrating them into the DE-CIX European and trans-continental interconnection ecosystem,” Ivanov explains.

For the market entry into the Nordics, Bulk Data Centers, a part of Bulk Infrastructure Group, will be the initial partner supporting DE-CIX from Day 1. Bulk Infrastructure is Norway’s leader in building and operating sustainable digital infrastructure, data center, colocation, fiber network and industrial real estate. The DE-CIX interconnection platforms will be available in the Bulk data centers in Oslo (OS-IX) and Kristiansand (Campus N01) (Norway), as well as Esbjerg (Campus DK01) (Denmark).

“This partnership with DE-CIX will further enhance the options for customers to interconnect and access a range of services in addition to the already low latency access to major markets combined with the greenest cheapest energy in Europe,” says Gisle M. Eckhoff, Executive Vice President Data Centers at Bulk Infrastructure. “We are seeing an increase in demand for low cost, highly sustainable solutions and with these new DE-CIX Nordics locations we are helping to support that gravity shift North. We are delighted to build on our previous investments to unlock the potential of the Nordics and look forward to working with DE-CIX to enable more customers to take advantage of renewable, long term sustainable data centers.”

The Internet Exchange operator’s expansion to Norway, Denmark and Finland will serve the regional connectivity needs, boosted by new transatlantic and intercontinental submarine cables bridging the Nordics with North America and Asia. DE-CIX will fully integrate the Nordic exchanges into the company’s existing leading carrier and data center neutral interconnection ecosystem – the largest such in not only Central and Southern Europe, consisting of more than 10 IXs (2100+ connected networks), but also North America, with currently 5 IXs (400+ connected networks).

The new DE-CIX Internet Exchanges in the Nordics will have presences in all relevant data center facilities in the respective markets.

With the new DE-CIX IX platforms in Norway, Denmark and Finland, the company is extending its global footprint to overall 32 locations in Europe, North America, the Middle East, and Asia. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world.

About Bulk Data Centers

Bulk Data Centers delivers resiliency, cost efficiency, scalability and sustainability without compromise and with a dedication to personalized service excellence. As a trusted advisor offering strategically located Nordic data centers, Bulk enables customers to reduce costs and environmental impact while supporting data with highly connected, 100 percent green-powered and ultra-flexible colocation, white space, build-to-suit data center solutions and powered land. Backed by decades of expertise, Bulk delivers turnkey digital infrastructure that takes the sustainability and business value of the Nordic data center to the next level.

About DE-CIX

DE-CIX (German Commercial Internet Exchange) is the world’s leading operator of Internet Exchanges. In total, in its 32 locations in Europe, North America, the Middle East, and Asia, DE-CIX interconnects over 2400 network operators (carriers), Internet service providers (ISPs), content providers, and enterprise networks from more than 100 countries, offering peering, cloud, and interconnection services. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world. DE-CIX in Frankfurt, Germany, with a data throughput of more than 10 Terabits per second (Tbps) and over 1000 connected networks, is one of the largest Internet Exchanges in the world.

Further information at www.de-cix.net

Link:

ClickThru

Social Media:

https://www.facebook.com/DECIX.Internet.Exchange/

https://www.facebook.com/bulkinfrastructure/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye